A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung
Derick H. M. Lau, MD, PhD
Advertisement
Articles by Derick H. M. Lau, MD, PhD
Advertisement
Latest Updated Articles
- Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
Published: July 2nd 2000 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – December 3, 2025
2
Lessons Learned From the Past 25 Years of Cell and Gene Therapy Research
3
FDA Activity Recap: November 2025 Features SMA Approval, Boxed Warning for Elevidys, and More
4
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
5
